A-427 Xenograft Model Service for NSCLC

The A-427 xenograft model provides a robust, clinically relevant platform for preclinical evaluation of therapeutic strategies in KRAS-driven non-small cell lung cancer (NSCLC), enabling researchers to assess drug efficacy, resistance mechanisms, and combination regimens within a well-characterized in vivo system. Alfa Cytology offers comprehensive A-427 xenograft model services tailored to your preclinical research needs, delivering validated tumor growth data, standardized protocols, and endpoint analysis to accelerate your oncology drug development pipeline.

Overview of A-427 Xenograft Model for NSCLC

The A-427 cell line was originally established by D.J. Giard from the lung adenocarcinoma of a 52-year-old Caucasian male patient and is classified as a non-small cell lung carcinoma (NSCLC) model. It exhibits epithelial morphology with adherent growth characteristics and carries a heterozygous KRAS G12D activating mutation, which drives sustained activation of downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling pathways. The cell line is wild-type for EGFR and BRAF, and retains functional p53 activity, making it particularly valuable for studying oncogenic KRAS-driven tumorigenesis in an EGFR-independent context. A-427 cells express epithelial lineage markers including cytokeratins and E-cadherin, while lacking neuroendocrine or squamous cell-specific features, supporting their use in targeted inhibitor testing and biomarker discovery across RAS-centric oncology studies.

In xenograft applications, A-427 tumors are typically established through subcutaneous injection into immunodeficient mice such as nude or NSG strains, with engraftment observed within 10–14 days and tumor volumes reaching 600–800 mm³ over 5–6 weeks. The model displays consistent take rates and uniform growth across cohorts, enabling reliable evaluation of drug efficacy in long-term dosing studies. Histologically, A-427 xenografts reveal moderately differentiated adenocarcinoma features with cohesive epithelial nests, glandular structures, eosinophilic cytoplasm, and prominent nucleoli. Immunohistochemistry confirms positivity for pan-cytokeratin, CK7, and E-cadherin, with Ki-67 reflecting moderate proliferative activity and phospho-ERK/phospho-AKT indicating persistent downstream KRAS pathway activation. This model is frequently employed to assess KRAS-targeted therapies, MEK or ERK inhibitors, and combination regimens involving DNA damage response modulators or immune checkpoint blockade in RAS-driven tumor settings.

Fig 1. Dynamics of BRD-810-induced killing suggests a short-term 1-h coverage of unbound IC₅₀ sufficient to induce antitumor efficacy in vivo. (Rauh, Ulrike, et al., 2024)

Cell Line Information: A-427

The A-427 cell line is a well-characterized human lung adenocarcinoma model with extensive documentation across multiple cell repositories. The following table summarizes its key biological, molecular, and culture characteristics:

Our Services

At Alfa Cytology, we provide end-to-end A-427 xenograft model services designed to support your preclinical oncology research from study design through data delivery. Our experienced scientific team ensures rigorous quality control, reproducible tumor growth curves, and comprehensive endpoint analyses—including tumor volume monitoring, body weight assessment, histopathological evaluation, and biomarker analysis—empowering you to make confident, data-driven decisions in your drug development pipeline. Whether you require standard subcutaneous xenografts, orthotopic implantation, or customized combination therapy protocols, Alfa Cytology delivers reliable, publication-ready results with fast turnaround times and dedicated project management support.

Workflow of A-427 Xenograft Model Construction

The construction of the A-427 xenograft model follows a standardized, multi-step workflow that ensures reproducible tumor engraftment, consistent growth kinetics, and reliable data generation for preclinical drug evaluation. Each phase is executed under strict quality control measures to maintain model integrity and experimental validity.

1. Cell Culture and Quality Verification: A-427 cells are expanded in vitro under standardized conditions (MEM-EBS + 10% FBS, 37°C, 5% CO₂) and verified for mycoplasma negativity, STR authentication, and viability (>95%) prior to implantation.
2. Animal Preparation and Acclimation: Immunodeficient mice (nude or NSG strains, 6–8 weeks old) are acclimated for at least one week under controlled environmental conditions, with baseline body weights and health status documented.
3. Tumor Cell Inoculation: A-427 cells are harvested at logarithmic growth phase, washed, resuspended in serum-free medium or Matrigel/medium mixture, and injected subcutaneously into the flank region (typically 1–5 × 10⁶ cells per mouse).
4. Tumor Monitoring and Randomization: Tumor engraftment is monitored by palpation and caliper measurement; upon reaching 100–150 mm³, mice are randomized into treatment and control cohorts to ensure balanced baseline tumor volumes.
5. Dosing and Treatment Administration: Test compounds are administered according to the study protocol (oral gavage, intraperitoneal, or intravenous routes), with dosing schedules, vehicle controls, and dose-escalation designs customized per client requirements.
6. In-Life Monitoring and Data Collection: Tumor dimensions and body weights are recorded at regular intervals (typically 2–3 times per week); clinical observations and adverse events are documented throughout the study duration.
7. Endpoint Analysis and Tissue Harvest: At study termination, tumors are excised, weighed, and photographed; tissues are preserved for histopathology (H&E, IHC), biomarker analysis (Western blot, qPCR), and pharmacokinetic/pharmacodynamic assessments.
8. Data Compilation and Reporting: All raw data, statistical analyses, tumor growth curves, and histopathological images are compiled into a comprehensive study report with publication-ready figures and detailed methodology descriptions.

Fig 2. A-427 xenograft model construction workflow.

Case Study-A-427 Xenograft Model Development

In a representative preclinical study, the A-427 xenograft model was successfully established in immunodeficient mice to evaluate the antitumor efficacy of a novel therapeutic candidate targeting the KRAS signaling axis. Following subcutaneous implantation, tumors exhibited consistent engraftment with predictable growth kinetics, enabling robust statistical comparison between treatment and vehicle control groups. The test compound demonstrated dose-dependent tumor growth inhibition, with significant reduction in tumor volume and weight observed at multiple dosing levels. Comprehensive endpoint analysis included histopathological examination confirming adenocarcinoma morphology, immunohistochemical staining for proliferation and pathway markers, and biomarker profiling to assess target engagement. These findings underscore the A-427 model's utility as a reliable platform for preclinical validation of KRAS-directed therapies in NSCLC. (Detailed quantitative data available upon request.)

Why Choose Alfa Cytology?

Alfa Cytology is a dedicated preclinical CRO specializing in tumor model services, offering scientifically rigorous, client-centered solutions to accelerate your oncology drug development programs. Our A-427 xenograft model service is built on validated protocols, experienced scientific staff, and comprehensive data packages tailored to your research objectives.

• Validated, authenticated A-427 cell lines with documented STR profiles and mycoplasma-negative certification ensure model integrity and reproducibility.
• Standardized xenograft protocols with consistent tumor take rates and predictable growth kinetics minimize experimental variability and accelerate data generation.
• Flexible study designs including subcutaneous, orthotopic, and combination therapy arms, customized to your compound's mechanism of action and development stage.
• Comprehensive endpoint analysis encompassing tumor volume monitoring, body weight assessment, histopathology (H&E and IHC), and biomarker quantification.
• Fast turnaround times with dedicated project management, ensuring seamless communication, real-time data access, and on-schedule report delivery.
• Publication-ready data packages with statistical analyses, high-resolution imaging, and detailed methodology descriptions to support regulatory and scientific submissions.

Contact Us

Ready to advance your NSCLC preclinical research with our validated A-427 xenograft model? Contact us today to discuss your study requirements, receive a customized proposal, and partner with Alfa Cytology for reliable, data-driven preclinical solutions. Our scientific team is standing by to reach out to you and guide your project from concept to completion with precision and expertise.

For research use only. Not intended for any clinical use.